The synthesis of advanced medical imaging agents like Iohexol relies heavily on the availability of high-purity intermediates. Among these, 5-Amino-2,4,6-triiodoisophthalic acid (CAS No. 35453-19-1) stands out as a crucial building block. As a manufacturer specializing in pharmaceutical intermediates, we understand the intricate processes and stringent quality controls necessary to produce this compound effectively. This article offers insights into its manufacturing, purity requirements, and its significance in the production of Iohexol and similar contrast media.

The Synthesis of 5-Amino-2,4,6-triiodoisophthalic Acid

The production of 5-Amino-2,4,6-triiodoisophthalic acid typically involves the iodination of 5-aminoisophthalic acid. A common method described in literature and patents involves reacting 5-aminoisophthalic acid with iodine in the presence of an oxidizing agent like iodic acid, often under acidic conditions and controlled temperatures. The process requires careful management of reaction parameters, including reagent stoichiometry, temperature, pH, and reaction time, to maximize yield and minimize the formation of byproducts. Subsequent purification steps, such as filtration, washing, and drying, are critical to achieve the required high purity.

Why High Purity Matters for Iohexol Production

Iohexol is a widely used nonionic X-ray contrast agent, known for its safety and efficacy. As an intermediate, 5-Amino-2,4,6-triiodoisophthalic acid contributes significantly to Iohexol's molecular structure, which is designed for optimal performance in diagnostic imaging. The presence of even trace impurities in the intermediate can:

• Impact Reaction Yield: Impurities can interfere with subsequent reaction steps, leading to lower yields of the desired final product.
• Affect Product Purity: If the intermediate is not pure, the final Iohexol product may contain impurities that could have adverse effects or require extensive and costly purification.
• Compromise Stability: Impurities can sometimes reduce the overall stability of the intermediate or the final product, affecting shelf life and performance.
• Cause Regulatory Issues: Pharmaceutical regulatory bodies have strict limits on impurities in active pharmaceutical ingredients (APIs) and their intermediates.

Manufacturers must therefore employ robust analytical methods, such as High-Performance Liquid Chromatography (HPLC), to verify purity levels, often targeting ≥98.5%. Other tests for loss on drying and residue on ignition are also standard practice.

Procurement and Supply Chain Considerations

For R&D scientists and procurement managers looking to buy 5-Amino-2,4,6-triiodoisophthalic acid, selecting a reputable manufacturer is paramount. Key considerations include:

• Manufacturing Expertise: Partner with manufacturers who have demonstrated expertise in producing complex organic intermediates, especially those involving halogenation.
• Quality Assurance Systems: A strong QA/QC system, including advanced analytical instrumentation and validated methods, is non-negotiable.
• Capacity and Scalability: Ensure the manufacturer can meet your current and future volume requirements, from R&D quantities to commercial-scale production.
• Competitive Pricing: While quality is primary, cost-effectiveness is also a factor, particularly for large-scale manufacturing. Requesting quotes from multiple suppliers can help identify the best value.

As a dedicated manufacturer, we are committed to providing pharmaceutical companies with the highest quality 5-Amino-2,4,6-triiodoisophthalic acid. Our advanced production facilities and stringent quality control ensure that our product meets the demanding specifications required for Iohexol synthesis and other critical applications. We encourage potential buyers to inquire about our manufacturing capabilities and request a quotation to discuss their specific needs.